The University of Tokyo's IPC1 Fund has invested approximately 200 million yen in Accurna Inc., supporting the company's innovative approach to nucleic acid drug delivery through advanced Nano DDS technology.

Target Company Overview

Accurna Inc., a venture associated with the University of Tokyo, focuses on developing innovative nucleic acid medicines using advanced Nano Drug Delivery System (Nano DDS) technology. Established in December 2015, Accurna is based in Bunkyo-ku, Tokyo, and is led by CEO Keiko Hattori. The company aims to implement scientific research results into practical applications, particularly in the field of nucleic acid drugs.

Nucleic acid medicines utilize substances like DNA and RNA as therapeutic agents, making it possible to target molecular pathways that traditional low molecular weight or antibody drugs cannot address. This advancing field has the potential to revolutionize drug discovery, although challenges remain regarding the stability and delivery of nucleic acids in the human body, necessitating innovative solutions for effective therapeutic application. Accurna's Nano DDS technology grants high bioavailability and reduced side effects, offering a versatile solution for various nucleic acid drugs while ensuring cost-effective, high-quality manufacturing.

Industry Overview in Japan

The life sciences and healthcare industry in Japan is experiencing significant growth, driven by advancements in technology and increasing healthcare demands. The country's aging